Overview

  • Product name

    Anti-TCF-4/TCF7L2 antibody
    See all TCF-4/TCF7L2 primary antibodies
  • Description

    Rabbit polyclonal to TCF-4/TCF7L2
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-P, ELISAmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human TCF-4/TCF7L2 (N terminal).

  • Positive control

    • Human kidney tissue; HeLa cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab134275 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/200 - 1/1000. Predicted molecular weight: 68 kDa.
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ELISA 1/80000.

Target

  • Function

    Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.
  • Tissue specificity

    Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.
  • Involvement in disease

    Note=Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).
    Genetic variations in TCF7L2 are associated with susceptibility to non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
  • Sequence similarities

    Belongs to the TCF/LEF family.
    Contains 1 HMG box DNA-binding domain.
  • Developmental stage

    Highly expressed in crypt regions and barely detectable in villi in epithelium from fetal small intestine at week 16. At week 22 expression in villi had increased strongly.
  • Domain

    The promoter-specific activation domain interacts with the transcriptional coactivator EP300.
  • Post-translational
    modifications

    In vitro, phosphorylated by TNIK.
    Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylated by AXAM/SENP2. Sumoylation/desumoylation regulates TCF4 transcription activity in the Wnt signaling pathway without altering interaction with CTNNB1 nor binding DNA.
  • Cellular localization

    Nucleus > PML body. Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.
  • Information by UniProt
  • Database links

  • Alternative names

    • HMG box transcription factor 4 antibody
    • hTCF 4 antibody
    • hTCF-4 antibody
    • T cell factor 4 antibody
    • T cell specific HMG box antibody
    • T cell specific transcription factor 4 antibody
    • T-cell factor 4 antibody
    • T-cell-specific transcription factor 4 antibody
    • TCF 4 antibody
    • TCF-4 antibody
    • TCF4 antibody
    • TCF7L2 antibody
    • TCF7L2 protein antibody
    • TF7L2_HUMAN antibody
    • Transcription factor 7 like 2 antibody
    • Transcription factor 7 like 2 T cell specific HMG box antibody
    • Transcription factor 7-like 2 antibody
    see all

Images

  • Immunohistochemical analysis of paraffin-embedded Human kidney tissue labelling TCF-4/TCF7L2 with ab134275 at 5µg/ml. Primary incubation was followed by biotinylated goat anti-rabbit IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.

  • Anti-TCF-4/TCF7L2 antibody (ab134275) at 1/500 dilution + HeLa cell lysate

    Predicted band size: 68 kDa

References

This product has been referenced in:

  • Chen KJ  et al. SIM2 maintains innate host defense of the small intestine. Am J Physiol Gastrointest Liver Physiol 307:G1044-56 (2014). Read more (PubMed: 25277798) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab134275.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up